^
Association details:
| Biomarker: | BCL2 expression |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + Gazyva (obinutuzumab) (CD20 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Combination of Obinutuzumab and Venetoclax in Relapsed or Refractory DLBCL
Excerpt:
...Bcl-2 protein expression detected by immunohistochemistry...
Trial ID:
Source:
Title:
3027 Phase II Single-Arm “Window-of-Opportunity” Study of a Combination of Obinutuzumab and Venetoclax in Early Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) – First Results of the AGMT NHL15B Study
Published date:
11/04/2020
Excerpt:
Twenty-one patients with DLBCL (relapsed within 12 months or primary refractory), detectable Bcl-2 protein expression and CD20 positivity were included in this prospective...The objective response rate was 38.1% (8/21 patients) with a best response of 5 CR (23.8%) and 3 PR (14.2%). Response duration was 83.3% at 84 days, with a progression-free survival of 38.8% at 84 days and 25.9% at 168 days and an overall survival of 59.3% at 168 days.
Trial ID:
